Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which scan sees hidden myeloma better: PET or MRI?

NCT ID NCT01309334

Diagnosis Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers compare PET scans and MRI to see which imaging method detects more myeloma lesions in adults under 65 with newly diagnosed multiple myeloma. Participants receive both scans at diagnosis, after three cycles of chemotherapy, and at the end of treatment. The study also tracks the cost of each scan. The goal is to learn which test gives doctors a clearer picture of the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PET scan and MRI imaging procedures
What this could lead to
If one scan proves better at finding hidden myeloma lesions, doctors could choose the more accurate test to guide treatment decisions.
What could go wrong
This is a comparison of two existing imaging methods, not a new treatment. Neither scan may clearly outperform the other, and results may not apply to older patients or those not receiving the same chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

152 people

The number who actually took part.

Start date

Feb 2011

Finished

Sep 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * symptomatic de novo multiple myeloma * less than 65 years of age * enrolled in the IFM/DFCI clinical trial Exclusion Criteria: * 66 years of age or more * not eligible for high-dose therapy * Cons-indications to MRI or PET-Scan

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • "Institut Paoli Calmettes"

    Marseille, France

  • APHP "Hôpital Saint-Antoine"

    Paris, France

  • Bordeaux University Hospital

    Bordeaux, France

  • Brest University Hospital "CHU du Morvan"

    Brest, France

  • Clermont-Ferrand University Hospital

    Clermont-Ferrand, France

  • Dijon University Hospital

    Dijon, France

  • Grenoble University Hospital "Hôpital Michallon"

    Grenoble, France

  • Hospital "Côte de Nacre"

    Caen, France

  • Le Mans Hospital

    Le Mans, France

  • Lille University Hospital "Claude Huriez"

    Lille, France

  • Lyon University Hospital

    Lyon, France

  • Metz University Hospital "Hôpital de Mercy"

    Metz, France

  • Nancy University Hospita "Hôpitaux de Brabois"

    Nancy, France

  • Nantes University Hospital

    Nantes, 44000, France

  • Rennes University Hospital

    Rennes, France

  • Toulouse University Hospital

    Toulouse, France

  • Tours University Hospital "Hôpital Bretonneau"

    Tours, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.